Professor Kausik Ray speaks to Cardio Debate and Radcliffe Cardiology about PCSK9 in the treatment of familial hypercholesterolaemia during the ESC Congress 2015 in London, UK.
PCSK9 a ‘game changer’ in the treatment of familial hypercholesterolaemia
Related articles
06/25/2018 - WOSCOPS analysis closes the LDL-C evidence gap - Sian Claire Owen, medical journalist for Cardio Debate, UK
04/09/2018 - Estimating the potential incremental benefit of treating CAD patients with PCSK9 inhibitors - Prof JC Kaski, St George's, University of London, UK
07/30/2017 - The rise of ‘statin denialism’ – is this a real risk? - Sian Claire Owen, Medical Journalist for Cardio Debate
07/09/2017 - Can a vaccine lower cholesterol and prevent heart attacks? - Sian Claire Owen, Medical Journalist for Cardio Debate
10/24/2016 - PCSK9 antagonists: A real breakthrough for management of familial hypercholesterolaemia? - Prof Ulf Landmesser, Charite - Universitatsmedizin, Berlin, Germany
09/09/2016 - Screening and patient awareness in familial hypercholesterolemia: Challenges for clinical practitioners - Prof Juan Carlos Kaski, St George's, University of London, UK
01/21/2016 - Advances in the Management of Dyslipidaemia (Part 3 of 3) - Prof Julian Halcox, Professor of Cardiology, Swansea University College of Medicine, UK
12/29/2015 - Novel treatment strategies for hypercholesterolaemia: can your patients benefit from PCSK9 inhibitors? - Dr Rachel Bastiaenen, PhD, St George's University of London, St George's Hospital London, UK
Leave a Reply
You must be logged in to post a comment.